Tonix Pharmaceuticals Exceeds Expectations in Q2 2026 with Strong Execution and Growth
Tonix Pharmaceuticals has reported strong financial results and operational highlights for the second quarter of 2026, exceeding expectations in its commercial business and advancing development pipeline.
According to Dr. Seth Lederman, Chief Executive Officer, the company is focused on improving care for patients with debilitating conditions or preventing illness before it happens. The launch of TONMYA, a treatment for fibromyalgia approved by the FDA in over 15 years, is progressing well, supported by growing sales and improvement across launch metrics.
Tonix achieved approximately $11 million in net sales for TONMYA in Q2 2026, representing 197% quarter-over-quarter growth. This significant increase can be attributed to patient and prescriber recognition of the value of TONMYA as well as Tonix's strategic focus and execution.
The company's commercial performance is also underscored by growing share of voice as the only branded and marketed product for fibromyalgia, reaching 100% share. With more than 10 million adults in the U.S. suffering from fibromyalgia, Tonix believes its launch performance highlights TONMYA's compelling value proposition and differentiated profile.
Tom Englese, Executive Vice President of Commercial Operations, highlighted the strategic expansion of the sales force, which will be fully implemented by September. This move is designed to capitalize on the broad coverage across commercial, managed Medicare, and Medicaid channels that represents approximately 136 million covered lives or 43% of the U.S. population.
This coverage is expected to lead to growth in patient access and net sales for the rest of the year and beyond. With the managed Medicare GPO coverage agreement set to become effective on January 1st, 2027, TONMYA coverage will represent approximately 145 million covered lives or approximately 46% of the U.S. population.
Tonix's development pipeline includes a carefully selected group of therapeutic and preventative candidates, each targeting large areas of unmet need. The company is strategically advancing these programs while executing on its commercial launch, further solidifying its position in the pharmaceutical industry.
